NovaBay Pharma (NBY) Reports NVC-422 Missed Endpoints in Phase 2
Tweet Send to a Friend
NovaBay Pharma (NYSE: NBY) announced that its NVC-422 ophthalmic formulation did not meet the primary or secondary endpoints in a ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
